Diphtheria antitoxin levels among children primed with a diphtheria and tetanus toxoids and acellular pertussis vaccine lot with a subpotent diphtheria toxoid component

Journal of Infectious Diseases

Volumn 183, Issue 11, 2001, Pages 1698-1700

  Jackson, Lisa A ^a,c   Falls, Sherry ^a   Yu, Onchee ^a   George, Jim ^b   Pietrobon, Patricia J ^b   Rubanowice, David ^a   Froeschle, James ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SANOFI PASTEUR   (France)

^c CENTER FOR HEALTH STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA ANTIBODY; DIPHTHERIA TOXOID; PERTUSSIS VACCINE; TETANUS TOXOID;

ANTIBODY BLOOD LEVEL; ARTICLE; CHILD; CONTROLLED STUDY; DIPHTHERIA; DISEASE CONTROL; DRUG POTENCY; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PERTUSSIS; PRIORITY JOURNAL; TETANUS; VACCINATION;

ANTIBODIES, BACTERIAL; DIPHTHERIA; DIPHTHERIA ANTITOXIN; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; HUMANS; IMMUNIZATION, SECONDARY; INFANT; PRODUCT SURVEILLANCE, POSTMARKETING; VACCINATION;

EID: 0035371247     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/320713     Document Type: Article

References (12)

1. Centers for Disease Control and Prevention. Notice to readers: recall of Tripedia (TM) vaccine. MMWR Morb Mortal Wkly Rep 1999;48:146-8.
2. Centers for Disease Control and Prevention. Summary of notifiable diseases, United States, 1998. MMWR Morb Mortal Wkly Rep 1999;47:1-93.
3. Mortimer EA Jr, Wharton M. Diphtheria toxoid. In: Plotkin SA, Orenstein WA, eds. Vaccines. 3d ed. Philadelphia: WB Saunders, 1999:140-57.
4. Orenstein WA, Weisfeld JS, Halsey NA. Diphtheria and tetanus toxoids and pertussis vaccine, combined. Publication 451. Washington, DC: Pan American Health Organization, World Health Organization, 1983:30-51.
5. Chen RT, Glasser JW, Rhodes PH, et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States, Pediatrics 1997;99:765-73.
6. Chen RT, DeStefano F, Davis RL, et al. The Vaccine Safety Datalink: immunization research in health maintenance organizations in the USA. Bull World Health Organ 2000;78:186-94.
7. Jackson LA, Benson P.Sneller VP, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999;281:243-8.
8. Davis RL, Marcuse E, Black S, et al. MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine Safety Datalink Team. Pediatrics 1997; 100:767-71.
9. Ray P, Black S, Shinefield H, et al. Risk of chronic arthropathy among women after rubella vaccination. Vaccine Safety Datalink Team. JAMA 1997; 278:551-6.
10. Pichichero ME, Francis AB, Marsocci SM, Green JL, Disney FA, Meschievitz C. Safety and immunogenicity of an acellular pertussis vaccine booster in 15- to 20-month-old children previously immunized with acellular or whole-cell pertussis vaccine as infants. Pediatrics 1993;91:756-60.
11. Pichichero ME, Deloria MA, Rennels MB, et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics 1997; 100:772-88.
12. Marcinak JF, Ward M, Frank AL, Boyer KM, Froeschle JE, Hosbach PH. Comparison of the safety and immunogenicity of acellular (BIKEN) and whole-cell pertussis vaccines in 15- to 20-month-old children. Am J Dis Child 1993; 147:290-4.